Venezuela incorporates EpiVacCorona vaccine into COVID-19 immunization campaign

Executive Vice-president Delcy Rodrígez announced the incorporation of the second vaccine developed by Russian scientists, EpiVacCorona, into Venezuela’s COVID-19 immunization campaign.

At the Miraflores Presidential Palace in Caracas, Rodríguez explained EpiVacCorona is a COVID-19 vaccine developed by the Vector Institute, located in Siberia, Russia, widely known for its contributions to HIV, Influenza and Ebola studies.

Likewise, she said that Venezuela is joining the phase of trials in order to immunize the Venezuelan population after the vaccine is authorized by experts, and highlighted that this vaccine contains fragments extracted from the virus synthetic peptide antigens that provoke an immune reaction against COVID-19 with a 100% effectivity.

The Venezuelan vice-president also mention the arrival of 50,000 Sputnik V doses as part of the agreements endorsed with the Russian Federation to bring more than 10 million doses in 2021.

Rodríguez reaffirmed Venezuela’s participation in the World Health Organization’s Covax program through the development of the Oil-for-Vaccines Plan to immunize 100% of the Venezuelan population.

Regarding Brazil’s pandemic panorama, Rodríguez voiced concern.

“Our brother country is undoubtedly of great concern to Venezuela, not only because it is a neighboring country, but because it is undergoing one of the worst sanitary crises in its history,” she said.

The Venezuelan vice-president said Brazil is still the second most affected country with a total of 12,573,615 COVID-19 cases, 313,866 deaths and 44,300 reported cases in the last 24 hours.